Latest & greatest articles for myocardial infarction

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on myocardial infarction or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on myocardial infarction and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for myocardial infarction

121. Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration Full Text available with Trip Pro

Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration Women with acute myocardial infarction (MI) undergoing mechanical reperfusion remain at increased risk of adverse cardiac events and mortality compared with their male counterparts. Whether the benefits of new-generation drug-eluting stents (DES) are preserved in women with acute MI remains unclear.To

2017 JAMA cardiology

122. Short- and Long-term Therapeutic Efficacies of Intravenous Transplantation of Bone Marrow Stem Cells on Cardiac Function in Rats with Acute Myocardial Infarction: A Meta-analysis of Randomized Controlled Trials. (Abstract)

Short- and Long-term Therapeutic Efficacies of Intravenous Transplantation of Bone Marrow Stem Cells on Cardiac Function in Rats with Acute Myocardial Infarction: A Meta-analysis of Randomized Controlled Trials.

2017 Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih

123. Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial Full Text available with Trip Pro

Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial In patients with a myocardial infarction (MI) 1 to 3 years earlier, treatment with ticagrelor + low-dose aspirin (ASA) reduces the risk of cardiovascular (CV) death, MI, or stroke compared with low-dose aspirin alone, but at an increased risk of major bleeding.The authors evaluated cost-effectiveness of ticagrelor + low-dose ASA in patients with prior MI within (...) the prior 3 years.The authors performed a prospective economic substudy alongside the PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) trial, which randomized 21,162 patients to ASA alone, ticagrelor 60 mg twice daily + low-dose ASA, or ticagrelor 90 mg twice daily + low-dose ASA. Medical resource use data were collected over a median 33-month follow-up. Costs

2017 EvidenceUpdates

124. Ventricular Arrhythmia after Acute Myocardial Infarction: ‘The Perfect Storm’ Full Text available with Trip Pro

Ventricular Arrhythmia after Acute Myocardial Infarction: ‘The Perfect Storm’ Ventricular tachyarrhythmias (VAs) commonly occur early in ischaemia, and remain a common cause of sudden death in acute MI. The thrombolysis and primary percutaneous coronary intervention era has resulted in the modification of the natural history of an infarct and subsequent VA. Presence of VA could independently influence mortality in patients recovering from MI. Appropriate risk assessment and subsequent (...) treatment is warranted in these patients. The prevention and treatment of haemodynamically significant VA in the post-infarct period and of sudden cardiac death remote from the event remain areas of ongoing study.

2017 Arrhythmia & electrophysiology review

125. Circulating Prolidase Activity in Patients with Myocardial Infarction Full Text available with Trip Pro

Circulating Prolidase Activity in Patients with Myocardial Infarction Collagen is a major determinant of atherosclerotic plaque stability. Thus, identification of differences in enzymes that regulate collagen integrity could be useful for predicting susceptibility to atherothrombosis or for diagnosing plaque rupture. In this study, we sought to determine whether prolidase, the rate-limiting enzyme of collagen turnover, differs in human subjects with acute myocardial infarction (MI) versus those

2017 Frontiers in cardiovascular medicine

126. Association of Genetic Variants Related to Serum Calcium Levels With Coronary Artery Disease and Myocardial Infarction. Full Text available with Trip Pro

Association of Genetic Variants Related to Serum Calcium Levels With Coronary Artery Disease and Myocardial Infarction. Serum calcium has been associated with cardiovascular disease in observational studies and evidence from randomized clinical trials indicates that calcium supplementation, which raises serum calcium levels, may increase the risk of cardiovascular events, particularly myocardial infarction.To evaluate the potential causal association between genetic variants related to elevated (...) serum calcium levels and risk of coronary artery disease (CAD) and myocardial infarction using mendelian randomization.The analyses were performed using summary statistics obtained for single-nucleotide polymorphisms (SNPs) identified from a genome-wide association meta-analysis of serum calcium levels (N = up to 61 079 individuals) and from the Coronary Artery Disease Genome-wide Replication and Meta-analysis Plus the Coronary Artery Disease Genetics (CardiogramplusC4D) consortium's 1000 genomes

2017 JAMA

127. Exploring the adaptive experiences of children with parents of myocardial infarction: A Qualitative Study Full Text available with Trip Pro

Exploring the adaptive experiences of children with parents of myocardial infarction: A Qualitative Study Cardiovascular diseases are the world's leading cause of mortality. These diseases are rooted in an unhealthy lifestyle. In order to confront this subject, it is essential to identify several risk factors that contribute to heart disease (HD) in people with different attitudes, values, beliefs, expectations and motivations. This study was therefore an attempt to explain the adaptive (...) experiences of children whose parents were involved in myocardial infarction since they were more likely subjected to get the so-called disease.To identify the risk factors and to clear ambiguity using a qualitative research method from the experiences of people at risk of the above mentioned disease.This qualitative study was a directed content analysis. Eighteen children (above 18 years old) of parents with a history of myocardial infarction participated, and were chosen with purposive sampling

2017 Electronic physician

128. Vitamin D Uptake in Patients Treated with a High-Dosed Purified Omega-3 Compound in a Randomized Clinical Trial Following an Acute Myocardial Infarction Full Text available with Trip Pro

Vitamin D Uptake in Patients Treated with a High-Dosed Purified Omega-3 Compound in a Randomized Clinical Trial Following an Acute Myocardial Infarction Fish is the natural dietary source of vitamin D. Reports on the influence of purified omega-3 fatty acids on its uptake are scarce.We investigated the impact of a purified high-dose omega-3 compound compared to corn oil on 25-hydroxyvitamin D [25(OH)D] levels following an acute myocardial infarction.228 patients were randomized 1:1 to receive

2017 Frontiers in cardiovascular medicine Controlled trial quality: uncertain

129. Accuracy of Medical Claims for Identifying Cardiovascular and Bleeding Events After Myocardial Infarction : A Secondary Analysis of the TRANSLATE-ACS Study Full Text available with Trip Pro

Accuracy of Medical Claims for Identifying Cardiovascular and Bleeding Events After Myocardial Infarction : A Secondary Analysis of the TRANSLATE-ACS Study Pragmatic clinical trial designs have proposed the use of medical claims data to ascertain clinical events; however, the accuracy of billed diagnoses in identifying potential events is unclear.To compare the 1-year cumulative incidences of events when events were identified by medical claims vs by physician adjudication and to assess (...) the accuracy of bill-identified events using physician adjudication as the criterion standard.This post hoc analysis of a clinical trial assessed the medical claims forms and records for all rehospitalizations at 233 US hospitals within 1 year of the index acute myocardial infarction (MI) of 12 365 patients enrolled in the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) study between April 1

2017 JAMA cardiology

130. Use of Prescription Smoking Cessation Medications After Myocardial Infarction Among Older Patients in Community Practice Full Text available with Trip Pro

Use of Prescription Smoking Cessation Medications After Myocardial Infarction Among Older Patients in Community Practice 28724116 2018 11 13 2380-6591 2 9 2017 Sep 01 JAMA cardiology JAMA Cardiol Use of Prescription Smoking Cessation Medications After Myocardial Infarction Among Older Patients in Community Practice. 1040-1042 10.1001/jamacardio.2017.2369 Pagidipati Neha J NJ Duke Clinical Research Institute, Duke University, Durham, North Carolina. Hellkamp Anne A Duke Clinical Research

2017 JAMA cardiology

131. Non-Steroidal Anti-Inflammatory Drug Use and the Risk of Acute Myocardial Infarction in the General German Population: A Nested Case–Control Study Full Text available with Trip Pro

Non-Steroidal Anti-Inflammatory Drug Use and the Risk of Acute Myocardial Infarction in the General German Population: A Nested Case–Control Study Use of non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with an increased relative risk of acute myocardial infarction (AMI), but the label warnings refer particularly to patients with cardiovascular risk factors. The magnitude of relative AMI risk for patients with and without cardiovascular risk factors varies between studies

2017 Drugs - real world outcomes

132. Acute myocardial infarction caused by myocardial bridging alone confirmed by using intravascular ultrasonography Full Text available with Trip Pro

Acute myocardial infarction caused by myocardial bridging alone confirmed by using intravascular ultrasonography 29354809 2018 11 13 2589-0514 3 4 2017 Dec Chronic diseases and translational medicine Chronic Dis Transl Med Acute myocardial infarction caused by myocardial bridging alone confirmed by using intravascular ultrasonography. 260-262 10.1016/j.cdtm.2017.05.001 Wu Na-Qiong NQ Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center (...) of Medical Sciences, Peking Union Medical College, Beijing 100037, China. eng Journal Article 2017 07 03 China Chronic Dis Transl Med 101679934 2095-882X Acute myocardial infarction Coronary angiography Intravascular ultrasonography Myocardial bridging 2016 11 23 2018 1 23 6 0 2018 1 23 6 0 2018 1 23 6 1 epublish 29354809 10.1016/j.cdtm.2017.05.001 S2095-882X(16)30129-3 PMC5747492 J Pathol. 1998 May;185(1):4-9 9713353 Mod Pathol. 1991 Jul;4(4):424-31 1924274 Mod Pathol. 1996 Aug;9(8):843-8 8871926 J

2017 Chronic diseases and translational medicine

133. Effect of Electronic Reminders, Financial Incentives, and Social Support on Outcomes After Myocardial Infarction: The HeartStrong Randomized Clinical Trial Full Text available with Trip Pro

Effect of Electronic Reminders, Financial Incentives, and Social Support on Outcomes After Myocardial Infarction: The HeartStrong Randomized Clinical Trial Adherence to medications prescribed after acute myocardial infarction (AMI) is low. Wireless technology and behavioral economic approaches have shown promise in improving health behaviors.To determine whether a system of medication reminders using financial incentives and social support delays subsequent vascular events in patients following

2017 EvidenceUpdates

134. A Prothrombotic Score Based on Genetic Polymorphisms of the Hemostatic System Differs in Patients with Ischemic Stroke, Myocardial Infarction, or Peripheral Arterial Occlusive Disease Full Text available with Trip Pro

A Prothrombotic Score Based on Genetic Polymorphisms of the Hemostatic System Differs in Patients with Ischemic Stroke, Myocardial Infarction, or Peripheral Arterial Occlusive Disease While twin studies indicate a genetic component in arterial thrombosis such as ischemic stroke, myocardial infarction (MI), or peripheral arterial occlusive disease (PAOD), the clinical relevance of hemostatic polymorphisms in arterial thrombosis is a matter of debate.We analyzed the prevalence of 13 hemostatic

2017 Frontiers in cardiovascular medicine

135. Effect of Pentoxifylline in Ameliorating Myocardial Injury in Patients With Myocardial Infarction Undergoing Thrombolytic Therapy: A Pilot Randomized Clinical Trial (Abstract)

Effect of Pentoxifylline in Ameliorating Myocardial Injury in Patients With Myocardial Infarction Undergoing Thrombolytic Therapy: A Pilot Randomized Clinical Trial Cell death following acute myocardial infarction (MI) is the hallmark pathology of cardiovascular disease, leading to considerable mortality and morbidity. Platelet and neutrophil activation and inflammatory cytokines, prominently TNF-α, play an important role in the development of cell death. Because pentoxifylline inhibits (...) platelet and neutrophil activation and reduces TNF-α, this study was performed to assess the potential benefit of pentoxifylline in the reduction of myocardial injury following acute MI. In this randomized clinical trial, 98 patients with acute MI were randomly divided into 2 groups. The intervention group received an oral dose of 1200 mg of pentoxifylline immediately before thrombolytic therapy (TLT). All patients received the same standard protocol for treatment of MI. Cardiac enzymes were checked

2017 EvidenceUpdates

136. Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy Full Text available with Trip Pro

Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy We sought to determine the association of clopidogrel reloading with in-hospital bleeding and mortality in contemporary practice.We examined clopidogrel reloading for ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI) patients on pre-admission clopidogrel therapy in the ACTION Registry-GWTG from 2009 to 2014. We used inverse probability

2017 EvidenceUpdates

137. Direct Comparison of 4 Very Early Rule-Out Strategies for Acute Myocardial Infarction Using High-Sensitivity Cardiac Troponin I Full Text available with Trip Pro

Direct Comparison of 4 Very Early Rule-Out Strategies for Acute Myocardial Infarction Using High-Sensitivity Cardiac Troponin I Four strategies for very early rule-out of acute myocardial infarction using high-sensitivity cardiac troponin I (hs-cTnI) have been identified. It remains unclear which strategy is most attractive for clinical application.We prospectively enrolled unselected patients presenting to the emergency department with symptoms suggestive of acute myocardial infarction (...) myocardial infarction was the final diagnosis in 451 (16%) patients. The LOD approach ruled out 453 patients (16%) with a sensitivity of 100% (95% confidence interval [CI], 99.2%-100%), the single cutoff 1516 patients (54%) with a sensitivity of 97.1% (95% CI, 95.1%-98.3%), the 1-hour algorithm 1459 patients (52%) with a sensitivity of 98.4% (95% CI, 96.8%-99.2%), and the 0/1-hour algorithm 1463 patients (52%) with a sensitivity of 98.4% (95% CI, 96.8%-99.2%). Predefined subgroup analysis in early

2017 EvidenceUpdates

138. Risk Stratification for Patients in Cardiogenic Shock After Acute Myocardial Infarction Full Text available with Trip Pro

Risk Stratification for Patients in Cardiogenic Shock After Acute Myocardial Infarction Mortality in cardiogenic shock (CS) remains high. Early risk stratification is crucial to make adequate treatment decisions.This study sought to develop an easy-to-use, readily available risk prediction score for short-term mortality in patients with CS, derived from the IABP-SHOCK II (Intraaortic Balloon Pump in Cardiogenic Shock) trial.The score was developed using a stepwise multivariable regression (...) analysis.Six variables emerged as independent predictors for 30-day mortality and were used as score parameters: age >73 years, prior stroke, glucose at admission >10.6 mmol/l (191 mg/dl), creatinine at admission >132.6 μmol/l (1.5 mg/dl), Thrombolysis In Myocardial Infarction flow grade <3 after percutaneous coronary intervention, and arterial blood lactate at admission >5 mmol/l. Either 1 or 2 points were attributed to each variable, leading to a score in 3 risk categories: low (0 to 2), intermediate (3

2017 EvidenceUpdates

139. Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial Full Text available with Trip Pro

Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial Intracoronary infusion of autologous nucleated bone marrow cells (BMCs) enhanced the recovery of left ventricular ejection fraction (LVEF) after ST-segment elevation myocardial infarction (STEMI) in the randomised-controlled, open-label BOOST trial. We reassessed the therapeutic potential of nucleated BMCs in the randomised placebo-controlled, double-blind

2017 EvidenceUpdates

140. Association of US Centers for Medicare and Medicaid Services Hospital 30-Day Risk-Standardized Readmission Metric With Care Quality and Outcomes After Acute Myocardial Infarction: Findings From the National Cardiovascular Data Registry/Acute Coronary Trea Full Text available with Trip Pro

Association of US Centers for Medicare and Medicaid Services Hospital 30-Day Risk-Standardized Readmission Metric With Care Quality and Outcomes After Acute Myocardial Infarction: Findings From the National Cardiovascular Data Registry/Acute Coronary Trea The US Centers for Medicare and Medicaid Services Hospital Readmissions Reduction Program penalizes hospitals with higher-than-expected risk-adjusted 30-day readmission rates (excess readmission ratio [ERR] > 1) after acute myocardial (...) infarction (MI). However, the association of ERR with MI care processes and outcomes are not well established.To evaluate the association between ERR for MI with in-hospital process of care measures and 1-year clinical outcomes.Observational analysis of hospitalized patients with MI from National Cardiovascular Data Registry/Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines centers subject to the first cycle of the Hospital Readmissions Reduction Program between

2017 JAMA cardiology